{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-221567","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2026-05-13T20:02:03+00:00","discovered_at":"2026-05-13T20:03:00.785430+00:00","generated_at":"2026-05-13T22:23:35.939879+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Spero posts Q1 net loss of $7.2M; tebipenem HBr PDUFA date June 18, 2026","bullets":["Net loss of $7.2M ($0.13 diluted EPS) vs $13.9M loss ($0.25 EPS) in Q1 2025.","Total revenue of $0.3M, down from $5.9M in prior-year quarter.","Cash and equivalents of $56.1M as of March 31, 2026; cash runway into 2028.","GSK-led NDA for tebipenem HBr in cUTI under FDA review with PDUFA date June 18, 2026.","R&D expenses fell to $2.9M from $13.6M due to Phase 3 trial completion."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-221567","json":"https://secwatch.observer/filing/0001193125-26-221567.json","markdown":"https://secwatch.observer/filing/0001193125-26-221567.md","text":"https://secwatch.observer/filing/0001193125-26-221567.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526221567/0001193125-26-221567-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526221567/d147628d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T22:23:35.939879+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}